Modern Aspects of Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in Children (Literature Review)

LYMPHOID TUMORS , , ,

AS Levashov1, TT Valiev1, AM Kovrigina2, AV Popa1, GL Mentkevich1

1 N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

2 Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Andrei Sergeevich Levashov, scientific worker, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel.: +7(916)233-05-75; e-mail: andreyslevashov@mail.ru

For citation: Levashov AS, Valiev TT, Kovrigina AM, et al. Modern Aspects of Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in Children (Literature Review). Clinical oncohematology. 2016;9(2):199–207 (In Russ).

DOI: 10.21320/2500-2139-2016-9-2-199-207

ABSTRACT

Anaplastic large cell lymphoma (ALCL) includes different types of the disease that are heterogeneous according to clinical, morphological, immunological, cytogenetic and molecular biological features. The review demonstrates not only main clinical and morphoimmunological characteristics of ALCL, but also presents data about expression and prognostic significance of STAT3, pSTAT3tyr705, and survivin (transcription factor). It demonstrates the value of defining the minimal disseminated disease (the minimal disseminated disease is evaluated using the PCR test before initiation of the treatment, and the minimal residual disease is evaluated during the treatment and after its completion), and clinical and molecular biological prognostic factors are also identified. There is still no a standard therapeutic regimen for pediatric ALCL patients. However, the following therapeutic protocols are considered most effective: NHL-BFM 90/95, CCG5941, SFOP-LM 89/91, UKCCSG, ALCL99-Vinblastine, POG АРО 9315, AIEOP LNH-92/97. Treatment outcomes are presented in this paper. Particular attention is paid to different molecular biological markers that allow further improvement of patients’ stratification in risk groups and possible use of target medications (multikinase inhibitors and monoclonal antibodies) improving the therapy outcomes.

Keywords: anaplastic large cell lymphoma, diagnosis, treatment, children.

Received: February 3, 2016

Accepted: February 10, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Reiter A. Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma. 2007;2007(1):285–96. doi: 10.1182/asheducation-2007.1.285.
  2. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. 1985;66(4):848–58.
  3. Piccaluga PP, Gazzola A, Mannu C, et al. Pathobiology of Anaplastic Large Cell Lymphoma. Adv Hematol. 2010:345053. doi:10.1155/2010/345053.
  4. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2008.
  5. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М.: МИА, 2007. С. 212.[Kovrigina AM, Probatova NA. Limfoma Khodzhkina i krupnokletochnye limfomy. (Hodgkin’s lymphoma and large cell lymphomas.) Moscow: MIA Publ.; 2007. pp. 212. (In Russ)]
  6. Валиев Т.Т., Морозова О.В., Ковригина А.М. и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология. 2012;51(1):3–9. [Valiev TT, Morozova OV, Kovrigina AM, et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children. Gematologiya i transfuziologiya. 2012;51(1):3–9. (In Russ)]
  7. Lamant L, McCarthy K, d’Amore E, et al. Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell. Lymphoma: Results of the ALCL99 Study. J Clin Oncol. 2011;29(35):4669–76. doi: 10.1200/JCO.2011.36.5411.
  8. Calzado-Villarreal L, Polo-Rodriguez I, Ortiz-Romerob PL, et al. Primary Cutaneous CD30+ Lymphoproliferative Disorders. Actas Dermosifiliogr. 2010;101(2):119–28. doi: 10.1016/s1578-2190(10)70598-9.
  9. Brugieres L, Deley MC, Pacquement H, et al. CD30 Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology. 1998;92(10):3591–8.
  10. Williams DM, Hobson R, Imeson J, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812–20. doi: 10.1046/j.1365-2141.2002.03482.x.
  11. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. 2001;97(12):3699–706. doi: 10.1182/blood.v97.12.3699.
  12. Burkhardt В., Oschlies I, Klapper W, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. 2011;25(1):153–60. doi: 10.1038/leu.2010.245.
  13. Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. 2008;111(3):1560–6. doi: 10.1182/blood-2007-07-100958.
  14. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic Large Cell Lymphoma Treated with a Leukemia-Like Therapy: Report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 Protocol. 2005;104(10):2133–40. doi: 10.1002/cncr.21438.
  15. Lowe EJ, Sposto R, Perkins SL, et al. Intensive Chemotherapy for Systemic Anaplastic Large Cell Lymphoma in Children and Adolescents: Final Results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52(3):335–9. doi: 10.1002/pbc.21817.
  16. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-Stage Large-Cell Lymphoma in Children and Adolescents: Results of a Randomized Trial Incorporating intermediate-Dose Methotrexate and High-Dose Cytarabine in the Maintenance Phase of the APO Regimen: A Pediatric Oncology Group Phase III Trial. J Clin Oncol. 2005;23(3):541–7. doi: 10.1200/jco.2005.11.075.
  17. Pillon M, Gregucci F, Lombardi A, et al. Results of AIEOP LNH-97 Protocol for the Treatment of Anaplastic Large Cell Lymphoma of Childhood. Pediatr Blood Cancer. 2012;59(5):828–33. doi: 10.1002/pbc.24125.
  18. Jacobsen E. Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type. The Oncologist. 2006;11(7):831–40. doi: 10.1634/theoncologist.11-7-831.
  19. Delsoll G, Brugieres L, Gaulard P, et al. Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative. Hematol Meet Rep. 2009;3(1):51–7.
  20. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. 2002;21(7):1038–47. doi: 10.1038/sj.onc.1205152.
  21. Weinberg OK, Seo K, Arber DA. Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol. 2008;39(9):1331–40. doi: 10.1016/j.humpath.2008.01.005.
  22. Khoury JD, Medeiros LJ, Rassidakis GZ, et al. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma. Clin Cancer Res. 2003;9:3692–9.
  23. Dourlat J, Liu W-Q, Florence S, et al. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity. 2009;91(8):996–1002. doi: 10.1016/j.biochi.2009.05.006.
  24. Schlette EJ, Medeiros LJ, Goy A, et al. Survivin Expression Predicts Poorer Prognosis in Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2004;22(9):1682–8. doi: 10.1200/JCO.2004.10.172.
  25. Nasr MR, Laver JH, Chang M. Expression of Anaplastic Lymphoma Kinase, Tyrosine-Phosphorylated STAT3, and Associated Factors in Pediatric Anaplastic Large Cell Lymphoma. Am J Clin Pathol. 2007;127(5):770–8. doi: 10.1309/fny8y4h6pk1v2mge.
  26. Zhang J, Wang P, Wu F, et al. Aberrant expression of the transcriptional factor twist 1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signalling. 2012;24(4):852–8. doi: 10.1016/j.cellsig.2011.11.020.
  27. Huang W, Li X, Yao X, et al. Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma. Exper Mol Pathol. 2009;86(2):121–6. doi:10.1016/j.yexmp.2008.11.012.
  28. Damm-Welk C, Klapper W, Oschlies I, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009;146(3):306–9. doi: 10.1111/j.1365-2141.2009.07754.x.
  29. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. 2010;115(16):3314–9. doi: 10.1182/blood-2009-11-251892.
  30. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK–positive anaplastic large-cell lymphoma. 2007;110(2):670–7. doi: 10.1182/blood-2007-02-066852.
  31. Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. 2014;123(3):334–7. doi: 10.1182/blood-2013-09-526202.
  32. Jaffe ES. What’s new on the horizon in T-cell lymphoma. [Internet] Available from: http://www.ercongressi.it/t-cell-slide/April%2027,%202015/01.%20T-cell%20world/1%20-%20Jaffe.pdf. (accessed 18.04.2016).
  33. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. 2014;124(9):1473–80. doi: 10.1182/blood-2014-04-571091.
  34. Wrobel G, Mauguen A, Rosolen A, et al. Safety Assessment of Intensive Induction Therapy in Childhood Anaplastic Large Cell Lymphoma: Report of the ALCL99 Randomised Trial. Pediatr Blood Cancer. 2011;56(7):1071– doi: 10.1002/pbc.22940.
  35. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. 2005;105(3):948–58. doi: 10.1182/blood-2004-03-0973.
  36. Le Deley MC, Rosolen A, Williams DM, et al. Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial. J Clin Oncol. 2010;28(25):3987–93. doi: 10.1200/JCO.2010.28.5999.
  37. Alexander S, Kraveka JM, Weitzman S, et al. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized Phase III Trial of APO versus a modified regimen with vinblastine: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61(12):2236–42. doi: 10.1002/pbc.25187.
  38. Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223–30. doi: 10.1016/j.bbmt.2009.09.021.
  39. Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056–61. doi: 10.1200/JCO.2008.20.1764.
  40. Mori T, Takimoto T, Katano N, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2005;132(5):594–7. doi: 10.1111/j.1365-2141.2005.05910.x.
  41. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)-Type First-Line Therapy: A BFM-Group Study. J Clin Oncol. 2011;29(22):3065–71. doi: 10.1200/JCO.2011.34.8417.
  42. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN30 (anti-CD30 mab) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–9. doi: 10.1111/j.1365-2141.2009.07740.x.
  43. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin’s Lymphoma and Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2007;25(19):2764–9. doi 10.1200/jco.2006.07.8972.
  44. Pro B., Advani R, Brice P, et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. doi: 10.1200/JCO.2011.38.0402.
  45. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med. 2010;363(19):1812–21. doi: 10.1056/NEJMoa1002965.
  46. Mosse YP. Safety and activity of crizotinib for pediatric patients with refractory solid tumors or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80. doi: 10.1016/s1470-2045(13)70095-0.
  47. Passerini CG, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt37 doi: 10.1093/jnci/djt378.
  48. National Cancer Insitute. A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited 2016 April 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT01979536?term=NCT01979536&rank=1. NLM Identifier: NCT01979536.
  49. Greengard Е, Mosse Y, Liu X, et al. Safety and tolerability of crizotinib in combination with chemotherapy for relapsed or refractory solid tumors or anaplastic large cell lymphoma: a Children’s Oncology Group phase I consortium study. J Clin Oncol. 2015;33(Suppl): Abstract 10058.
  50. Geoerger B. Phase I study of ceritinib (Zycadia) in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy J Clin Oncol. 2015;33(Suppl): Abstract 10005.
  51. Friboulet L, Li N, Katayama R, et al. The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung cancer. Cancer Discovery. 2014;4(6):662–73. doi: 10.1158/2159-8290.CD-13-0846.